The role of survivin in thyroid tumors: Differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers

Thyroid

Volumn 24, Issue 3, 2014, Pages 511-519

  Pannone, Giuseppe ^a   Santoro, Angela ^b   Pasquali, Daniela ^c   Zamparese, Rosanna ^d   Mattoni, Marilena ^a   Russo, Giuseppe ^a   Landriscina, Matteo ^a   Piscazzi, Annamaria ^a   Toti, Paolo ^e   Cignarelli, Mauro ^a   Lo Muzio, Lorenzo ^a   Bufo, Pantaleo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Mazzoni Hospital   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; HORSERADISH PEROXIDASE; NUCLEAR PROTEIN; STREPTAVIDIN; SURVIVIN;

ADULT; AGED; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CYTOPLASM; DIFFERENTIATED THYROID CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON WELL DIFFERENTIATED THYROID CANCER; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THYROID CARCINOMA; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84896767813     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0196     Document Type: Article

References (59)

1. Sprague BL, Warren Andersen S, Trentham-Dietz A 2008 Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes Control 19:585-593.
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) 2010 SEER cancer statistics review 1975-2007. Available at: http://seer.cancer .gov/csr/1975-2007 (accessed 2010).
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
5. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1105.
6. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
7. Fonseca E, Soares P, Rossi S, Sobrinho-Simoes M 1997 Prognostic factors in thyroid carcinomas. Verhandlungen der Deutschen Gesellschaft fur Pathologie. Vol. 1. Stuttgort, Fischer, Germany, pp. 82-96.
8. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573.
9. LiVolsi VA, Fadda G, Baloch ZW 2000 Prognostic factors in well-differentiated thyroid cancer. Rays 25:163-175.
10. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR 1998 Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National thyroid cancer treatment cooperative study registry group. Cancer 83:1012-1021.
11. Deveraux QL, Reed JC 1999 IAP family proteins - suppressors of apoptosis. Genes Dev 13:239-252.
12. Salvesen GS, Duckett CS 2002 IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410.
13. Ambrosini G, Adida C, Altieri DC 1997A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
14. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC 2000 Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97:13103-13107.
15. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC 2002 Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62:2462-2467.
16. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC 1998 Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882-883.
17. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N 1998 Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074.
18. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ 2000 Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645-650.
19. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A 1999A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17:2100-2104.
20. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N 2000 Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134.
21. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC 1999 Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341:452-453.
22. Altieri DC 2001 The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542-547.
23. Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo A, Carinci F 2009 Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. J Cancer Res Clin Oncol 135:107-116.
24. Li F, Yang J, Ramnath N, Javle MM, Tan D 2005 Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509-512.
25. Huang Y, Chen X, Chen N, Nie L, Xu M, Zhou Q 2011 Expression and prognostic significance of survivin splice variants in diffusely infiltrating astrocytoma. J Clin Pathol 64:953-959.
26. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) 2004 World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon.
27. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds) 2010 The AJCC Cancer Staging Manual, 7th edition. Springer-Verlag, New York, pp 87-96.
28. Zamparese R, Pannone G, Santoro A, Lo Muzio L, Corsi F, Pedicillo MC, Scillitani EL, Tortorella S Staibano S, Piscuoglio S, Lo Russo L, and Bufo P 2008 Survivin expression in renal cell carcinoma. Cancer Invest 26:929-935.
29. Fedele M, Franco R, Salvatore G, Paronetto MP, Barbagallo F, Pero R, Chiariotti L, Sette C, Tramontano D, Chieffi G, Fusco A, Chieffi P 2008 PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J Pathol 215:39-47.
30. Landriscina M, Fabiano A, Altamura S, Bagalà C, Piscazzi A, Cassano A, Spadafora C, Giorgino F, Barone C, Cignarelli M 2005 Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 90:5663-5671.
31. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD 2002 Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9:1334-1342.
32. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Ernest L, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 12:109-142.
33. Nucera C, Lawler J, Hodin R, Parangi S 2010 The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget 1:751-756.
34. Folkman J, Ingber KWD, Hanahan D 1989 Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
35. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670.
36. Shibuya M, Claesson-Welsh L 2006 Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549-560.
37. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W 2012 SCF(b-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med 209:1289-1307.
38. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC 2002 Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115:575-585.
39. Dohi T, Beltrami, E, Wall NR, Plescia J, Altieri DC 2004 Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114:1117-1127.
40. Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS, Kim TY 2006 Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 60:289-292.
41. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggio MA, Procaccini M, Ferrari F, De Rosa G, Altieri DC 2003 Survivin expression in oral squamous cell carcinoma. Br J Cancer 89:2244-2248.
42. Xiang C, Liu WS, Jia SS 2007 Expression of survivin gene in thyroid carcinoma and its significance. Zhonghua Yi Xue Za Zhi 87:1761-1763.
43. Dong W, Li X, Lu X, Di B, Ma J, Cui L 2006 Expression of survivin and its correlation with tumor angiogenesis in differentiated thyroid carcinomas. Lin Chuang Er Bi Yan Hou Ke Za Zhi 20:967-969.
44. Zhang HY, Meng X, Du ZX, Fang CQ, Liu GL, Wang HQ, DengWW2009 Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin Exp Med 9:207-213.
45. Haghpanah V, Shooshtarizadeh P, Heshmat R, Larijani B, Tavangar SM 2006 Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl Immunohistochem Mol Morphol 14:422-425.
46. Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A 2003 Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep 10:1337-1340.
47. Chen Z, Liu N, Zhu G, Dralle H, Hoang-Vu C 2012 Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma. Int J Mol Med 30:465-472.
48. Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, Mirmiran A, Khorsandi MT, Larijani B, Mostaan LV, Amoli MM 2012 Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 208:100-103.
49. Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, Vigneri P 2006 Apr 15 Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 66:4263-4272.
50. Antonaci A, Consorti F, Mardente S, Natalizi S, Giovannone G, Della Rocca C 2008 Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep 20:63-67.
51. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD 1999 Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59:6097-6102.
52. Altura RA, Olshefski RS, Jiang Y, Boué DR 2003 Nuclear expression of survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer 89:1743-1749.
53. Grabowski P, Griss S, Arnold CN, Hörsch D, Göke R, Arnold R, Heine B, Stein H, Zeitz M, Scherübl H 2005 Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 81:1-9.
54. Martinez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D 2004 Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164:501-510.
55. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y 2001 Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163:109-116.
56. Tonini G, Vincenzi B, Santini D, Scarpa S, Vasaturo T, Malacrino C, Coppola R, Magistrelli P, Borzomati D, Baldi A, Antinori A, Caricato M, Nuzzo G, Picciocchi A 2005 Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer 92: 2225-2232.
57. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G 2004 Nuclear localization of survivin is a positive prognostic factor for survival in advanced nonsmall-cell lung cancer. Ann Oncol 15:1654-1660.
58. Vandghanooni S, Eskandani M, Montazeri V, Halimi M, Babaei E, Feizi MA 2011 Survivin-deltaEx3: a novel biomarker for diagnosis of papillary thyroid carcinoma. J Cancer Res Ther 7:325-330.
59. Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M 2006 Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging 33:179-183.